BIO-TECHNE Corp (TECH) Risk Factors

Recent key developments

Concrete developments — dated events, named agreements and instruments, legal proceedings — that BIO-TECHNE Corp surfaced in its latest filing.

• Russia's military invasion of Ukraine has caused severe political, humanitarian and economic crises, with trade restrictions on certain foods and energy supplies that increased prices, led to widespread inflation and otherwise aggravated economic challenges.
• At the beginning of this fiscal year, we invested in Spear Bio.beginning of fiscal year 2026
• At the beginning of fiscal year 2024 we completed the acquisition of Lunaphore, a leading developer of fully automated spatial biology solutions.beginning of fiscal year 2024
• Bio-Techne obtained a 19.9% ownership stake in Wilson Wolf and will acquire the remaining ownership no later than the end of calendar year 2027.end of calendar year 2027
• Exosome Diagnostics business develops and sells novel exosome-based diagnostic tests and has received public payer coverage for certain indications.
• The U.S. government recently announced its intention to regulate lab developed tests.
• Beginning in early April 2025, the U.S. implemented and/or announced tariffs on imports from a wide range of countries, and a number of countries imposed retaliatory tariffs and/or changes to existing tariffs, with significant tariffs between the U.S. and China remaining in effect.early April 2025
• Credit Agreement provides for a $1 billion revolving credit facility, expandable by an additional $400 million, with $313 million drawn as of August 16, 2025.August 16, 2025
• We anticipate additional impact from the One Big Beautiful Bill Act.
• The EU IVDR imposes stricter requirements for in vitro diagnostic medical devices, requiring material modifications to our quality management systems, additional resources, updates to technical files, and additional clinical data.
• We have continued participating in our collaborative marketing venture, ScaleReady LLC, with Wilson Wolf and another partner.
• Congress and the U.S. administration have sought to impose changes to healthcare in the United States, including government negotiation/regulation of drug prices paid by government programs.